目的 探討體位指導對產程的影響。 方法 選擇2007年1月-2008年1月產科住院的經特殊體位管理分娩的260例產婦，作為觀察組；同期未予以體位指導的經陰道分娩的260例產婦作為對照組，產程中未作體位指導，一般以平臥為主。觀察兩組產程進展情況、胎兒宮內窘迫、剖宮產率等。 結果 觀察組與對照組相比，第1產程及第2產程明顯縮短，胎兒宮內窘迫、剖宮產率明顯降低，有統計學意義（P＜0.05）。 結論 對孕婦實行體位管理能加快產程，避免各種產科并發癥的發生，增加了陰道分娩率，減少了剖宮產率。
Objective To summarize the latest developments in neurosurgical treatments for neurofibromatosis type 1 (NF1) and explore therapeutic strategies to provide comprehensive treatment guidelines for clinicians. Methods The recent domestic and international literature and clinical cases in the field of NF1 were reviewed. The main types of neurological complications associated with NF1 and their treatments were thorough summarized and the future research directions in neurosurgery was analyzed. Results NF1 frequently results in complex and diverse lesions in the central and peripheral nervous systems, particularly low-grade gliomas in the brain and spinal canal and paraspinal neurofibromas. Treatment decisions should be made by a multidisciplinary team. Symptomatic plexiform neurofibromas and tumors with malignant imaging evidence require neurosurgical intervention. The goals of surgery include reducing tumor size, alleviating pain, and improving appearance. Postoperative functional rehabilitation exercises, long-term multidisciplinary follow-up, and psychosocial interventions are crucial for improving the quality of life for patients. Advanced imaging guidance systems and artificial intelligence technologies can help increase tumor resection rates and reduce recurrence. Conclusion Neurosurgical intervention is the primary treatment for symptomatic plexiform neurofibromas and malignant peripheral nerve sheath tumors when medical treatment is ineffective and the lesions progress rapidly. Preoperative multidisciplinary assessment, intraoperative electrophysiological monitoring, and advanced surgical assistance devices significantly enhance surgical efficacy and safety. Future research should continue to explore new surgical techniques and improve postoperative management strategies to achieve more precise and personalized treatment for NF1 patients.